LivingGLP1
Study S000961

Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Obese and HFpEF: A Randomized Controlled Trial

Registration

Registration
NCT07630454
Acronym
TEAR-AF-HFpEF
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
SINGLE
Status
NOT_YET_RECRUITING
Enrollment
602
Start
2026-08-01
Primary completion
2029-08-01
Lead sponsor
Yunlong Wang
Conditions
Atrial Fibrillation; Heart Failure With Preserved Ejection Fraction (HFpEF); Tirzepatide
Interventions
DRUG:Tirzepatide; BEHAVIORAL:Structured Lifestyle Intervention
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • Number of Participants With Recurrence of atrial fibrillation, atrial flutter, or atrial tachycardia [Day 91 through Week 52 after catheter ablation]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.